Johnson & Johnson posts rise in fourth-quarter sales
Sales at Johnson & Johnson have risen 4.5% for the fourth quarter of 2013 against the same period in 2013, the company has announced, with the income totalling $18.4 billion.
J&J said: “Worldwide pharmaceutical sales of $28.1 billion for the full-year 2013 represented an increase of 10.9% versus the prior year, with an operational increase of 12.0% and a negative impact from currency of 1.1%.”
“Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our pharmaceutical business, the strength of key brands in our US OTC and other consumer businesses and continued progress in integrating Synthes into our medical devices and diagnostics business.
“We also advanced our longer-term growth drivers, bringing innovative solutions to the global healthcare market and executing with excellence.”
Alex Gorsky, chairman and chief executive, Johnson & Johnson.
Johnson & Johnson reports 2013 fourth-quarter and full-year results (Johnson & Johnson press release).
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.